Vertex Begins Phase 3 Triple Combo Therapy

Vertex Pharmaceuticals has launched the first Phase 3 clinical trial investigating the triple combination therapy of VX-659, tezacaftor (VX-661), and Kalydeco (ivacaftor) in cystic fibrosis (CF) patients with one F508del mutation and one minimal function mutation in the CFTR gene, which is defective in CF patients.

This triple combination trial is enrolling 360 CF patients ages 12 or older with one F508del mutation and one minimal function mutation at sites in the U.S., U.K., Canada, Australia, Denmark, Germany, Ireland, Israel, Norway, Poland, Spain, and Switzerland.

CFWA encourages all people living with CF to talk to their CF clinician about how they can participate in clinical trials. The reason for this is that CF is a rare disease and its often quite difficult for researchers to find enough people who qualify for the trials as they may already be involved in one trial or have to come off an effective treatment to participate in a new one with unknown outcomes.

For more details see the Cystic Fibrosis News Today press release.


Enquiries

For media enquiries please contact our Business Development Manager

Newsletter

Sign up for our newsletter!

2018 © Cystic Fibrosis Western Australia Privacy Policy | Refund & Delivery Policy | ABN: 19 156 339 182